NEW YORK, Aug. 9 (GenomeWeb News) - Shares in Sequenom were down 5.21 percent, or $.05, at $.91 in mid-afternoon trading after the company yesterday reported a slight increase in second-quarter revenues as losses slid sharply on lower costs.
Registering provides access to this and other free content.
Already have an account?Login Now.
In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.
Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.
The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.
Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.